Member Info for Num4

Indeed Thoth, I've emailed the firm and will let people know the reply.
As for this silence it is incomprehensible that we don't get an RNS on Monday highlighting the fact, fact, we have an institutional investor onboard. Parker's task was II and he's still tweeting about cannabis or whatever it is.
As has been mentioned by others, we play the AIM game all wrong, We bundle everything into one RNS instead of building some momentum. Patience is about to be rewarded.

Could be this fund within FPA, This is 30th June though and Sareum are not listed.

https://fpa.com/docs/default-source/funds/fund-holdings/fpa-international-holdings-2q20.pdf?sfvrsn=4

Milestone is worth £4million to Sareum not 8. Apologies.

I jump on most of their postings and have a dig, as do others. It may stop soon...it may get worse with big funds being squirreled away

"reducing indebtedness as applicable"

That's only us isn't it.. Sierra a different beast with Dilly, we will see. Then we can stop hijacking their Twitter posts about momly. Lol

We will retain broad discretion over the use of the net proceeds to us from the sale of our securities under this prospectus. Unless otherwise provided in the applicable prospectus supplement, we intend to use the net proceeds from the sale of securities under this prospectus for general corporate purposes, which may include funding research, clinical and process development and manufacturing of our product candidates, pre-commercial activities, increasing our working capital, reducing indebtedness as applicable, acquisitions or investments in businesses, products or technologies that are complementary to our own and capital expenditures. We will set forth in the applicable prospectus supplement our intended use for the net proceeds received from the sale of any securities. Pending the application of the net proceeds, we intend to invest the net proceeds in short-term or long-term, investment-grade, interest-bearing securities.

Let's hope not.

"While we have currently suspended development of SRA737, we are exploring options for potential future development of this product candidate, if any. However, there can be no assurance that we will successfully obtain development support or the funding necessary to advance SRA737 on commercially reasonable terms, or at all. If we are unable to obtain such support or funding, we may need to permanently cease development of SRA737."

Talk like this will enable the return to CPF, how good are the lawyers though as SRA141 got licensed back to Carna.

"For example, in June 2020, we licensed SRA141 back to Carna Biosciences, the original licensor. We will be entitled to certain profit share on royalty and non-royalty income and royalties on product sales. If Carna Biosciences or its collaborators fail to successfully develop and commercialize SRA141, we will receive limited to no value from this transaction."

your reading the 8, read the 10-Q

https://sec.report/Document/0001193125-20-211302/0001193125-20-211302.txt

It may give us some direction, are they still selling on or otherwise, not expecting great things but we should be able to read between the lines, as usual. The worst outcome is a copy and paste from the last one, any SP drop will be bought in to imo.

Sierra 10-Q tomorrow. Hunch.

LUCAN - publically displayed in a place not too hard to find:
http://www.sareum.com/discovery/overview/

Also mentioned in quoteddata article:
https://quoteddata.com/research/sareum-holdings-potential-strategy-covid19-2/

You're welcome Blastoid, if you're serious amount your investing here then keep on top of the research, it's flowing fast at the minute. Just wish our chairman would start the PR on twitter for all of this research with comments relating it to Sareums compounds, yet he chooses to pump some cannabis product - this will be a question at the upcoming results Stephen so you best get on the Sareum PR or have a damn good reason for your lack of effort.

Further reading, now I do recognize Figure 1 from somewhere....

https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(20)30143-7

This grant application will have substantial evidence from the pharma World for the sums requested.

Interesting that Sierra had presence here:
https://jak-drugdevelopment.com/?utm_source=external-pharma-phorum&utm_medium=press-release&utm_campaign=17818-jak-pharma-phorum-pr-hit-jakpot-covid19

Would Sareum sign another deal with Sierra...Erm....NO! Their momly is Jak so that explains that, interesting though.

Recent article summarising the existing trials for Jak inhibitors in COVID, take a look at all those black box warnings in the table.
https://erj.ersjournals.com/content/early/2020/07/02/13993003.01919-2020#T1

Now also read this statement"JAKi have a purported advantage over other immunomodulatory strategies in COVID-19, as they may exert dual anti-inflammatory (blockade of multiple, pro-inflammatory cytokines simultaneously) and anti-viral effects (impeding cellular viral endocytosis [5, 6]) and have convenient oral administration, with relatively short half-lives. JAKi may interrupt the signalling of several pro-inflammatory cytokines implicated in the pathogenesis of hyperinflammation, including interleukin (IL)-6, which has been the focus of several clinical trials in COVID-19. JAKi may also inhibit the entry of the SARS-CoV-2 virus into the AT2 alveolar epithelial cells; baricitinib (a JAK1/2 inhibitor), is a numb-associated kinase (NAK) inhibitor, with a particularly high affinity for AP2-associated protein kinase 1 (AAK1), a pivotal regulator of clathrin-mediated viral endocytosis [5]."

Sareum have a Jak inhibitor which has been designed to avoid these black box warnings for clots and DVT - again, a perfect position to be in.

Nothing is sending this back to previous levels, the way we have sustained this price is not the normal for Sareum, the only way is up.

Pfizer have also announced their tofa trial in COVID, with a start date of 7th August,
https://clinicaltrials.gov/ct2/show/NCT04469114

As all the LTH know, we have clear and compelling evidence of superiority in animal models over Pfizers tofa. It's a matter of time people, a matter of time.

All,

We know that Sareum is in the process of applying for the grant, so that is a fact - we will get news of this when the approval comes through. Now, what amount will Tim and John go for? I'd like to suggest that they will apply for enough funding to take TYK2 to PI/II, when you look at the amounts being granted:
https://www.gov.uk/government/publications/innovate-uk-transactions-over-25000

16million was granted to Cell Therapy Catapult Ltd. Let's digest that properly and have another think of the strategy here. Sareum could and should apply for a staged grant to take tyk2 to clinic, similar to the strategy Theravance is taking with their pan-jak inhibitor TD-0903.

Tim and John might just be about to get a golden ticket from the government, they have the differentiation through the tyk2 selectivity and plenty of evidence that JAK inhibitors can work. A £10million+ grant here may just be on the cards. It has taken them a while to prepare this submission so it must be well detailed and certainly a serious application - they are not just going for a few thousand imo, this is the perfect storm for Sareum as the de-risk for onlicense of autoimmune targets is worth millions to pharma.

Finish at 1p today, over and out

As mentioned, if a large buy order is in for under 1p they, as they have been doing, will fish for sellers until they let it go - I think they know they need to take it up to make a market here, every drop has been bought into for over a week now. Fun and games ahead, good luck to all, we've waited long enough - off for some beers in the sunshine.